High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors.

When the analysis was focused solely on the V600K BRAF mutation, we only observed a trend between nVAF and PFS, though it did not reach statistical significance (Supplementary Fig. 7 a).

also in 111,027 other papers